Core Viewpoint - The announcement by Bohui Innovation regarding the introduction of strategic investor Tongying Group and the capital increase for its subsidiary Hebei Bohui highlights significant developments in the company's growth strategy and operational expansion [2]. Group 1: Strategic Investment - On August 5, 2019, the sixth board of directors of Bohui Innovation approved the introduction of Tongying Group as a strategic investor for its subsidiary Hebei Bohui [2]. - Tongying Group will invest by transferring 120 million shares (72% ownership) of Bohui Biological Pharmaceutical Co., Ltd. and providing cash of 446.75 million yuan for the capital increase [2]. Group 2: Operational Commitments - Tongying Group has committed to ensuring that five plasma collection stations in Luyuan, Yaoan, Shenzhou, Linxi, and Pingdu obtain necessary qualifications and pass inspections within 18 months after the share transfer [2]. - A supplementary agreement was signed in December 2021 to further solidify the investment terms and operational commitments [2]. Group 3: Recent Developments - On February 4, 2026, the eighth board of directors approved a supplementary agreement regarding the approval process for three plasma collection stations in Luyuan, Yaoan, and Pingdu [2]. - This supplementary agreement does not require approval from the company's shareholders [2].

Core Viewpoint - The announcement indicates that the company’s subsidiary, Bohui Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for a lyophilized rabies vaccine, which is intended to stimulate immune response against rabies [1] Group 1: Company Developments - Bohui Innovation announced that its subsidiary has jointly applied for a rabies vaccine with Beijing Baihui Biotechnology Co., Ltd. [1] - The rabies vaccine is designed to prevent rabies by using purified rabies virus antigens to stimulate the immune response [1] - The approval for clinical trials is a significant step in the vaccine development process, although the company notes that drug development involves high investment, high risk, and long cycles [1] Group 2: Market Context - Currently, the domestic market for human rabies vaccines includes manufacturers such as Chengdu Kanghua Biological Products Co., Ltd. and Beijing Minhui Biotechnology Co., Ltd. [1] - The company acknowledges potential risks associated with drug development, including clinical trial outcomes not meeting expectations and delays in regulatory approvals or market entry [1] - The approval for the clinical trial is not expected to have a significant impact on the company's short-term performance [1]

Core Viewpoint - The company BoHui Innovation (300318.SZ) announced that its subsidiary BoHui Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of a lyophilized Haemophilus influenzae type b (Hib) conjugate vaccine [1] Group 1 - The lyophilized Hib conjugate vaccine is developed in collaboration with Beijing Baihui Biotechnology Co., Ltd. [1] - The vaccine aims to stimulate immune response through a purified Hib capsular polysaccharide antigen combined with tetanus toxoid, targeting invasive infections caused by Hib, such as meningitis, pneumonia, sepsis, cellulitis, arthritis, and epiglottitis [1]

Core Viewpoint - The company announced that its subsidiary, Bohui Biopharmaceutical Co., Ltd., in collaboration with Beijing Baihui Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of a lyophilized type B Haemophilus influenzae conjugate vaccine [1] Group 1 - The clinical trial approval indicates progress in the development of the vaccine, which may enhance the company's product portfolio in the biopharmaceutical sector [1] - The collaboration with Beijing Baihui Biotechnology Co., Ltd. suggests a strategic partnership aimed at leveraging combined expertise for vaccine development [1]